These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 16489095

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI, Khleif SN, Bergmann-Leitner ES, Kantor JA, Chung Y, Hamilton JM, Schlom J.
    Cell Immunol; 1997 Dec 15; 182(2):137-51. PubMed ID: 9514698
    [Abstract] [Full Text] [Related]

  • 3. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
    Bergmann-Leitner ES, Kantor JA, Shupert WL, Schlom J, Abrams SI.
    Cell Immunol; 1998 Aug 01; 187(2):103-16. PubMed ID: 9732698
    [Abstract] [Full Text] [Related]

  • 4. Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21.
    Abrams SI, Dobrzanski MJ, Wells DT, Stanziale SF, Zaremba S, Masuelli L, Kantor JA, Schlom J, Masuelle L [corrected to Masuelli L].
    Eur J Immunol; 1995 Sep 01; 25(9):2588-97. PubMed ID: 7589131
    [Abstract] [Full Text] [Related]

  • 5. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL, Crew MD, Santin AD, O'Brien TJ, Cannon MJ.
    Clin Cancer Res; 2005 May 01; 11(9):3446-54. PubMed ID: 15867247
    [Abstract] [Full Text] [Related]

  • 6. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [Abstract] [Full Text] [Related]

  • 7. Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model.
    Kubuschok B, Schmits R, Hartmann F, Cochlovius C, Breit R, König J, Pistorius G, Schilling M, Renner C, Pfreundschuh M.
    Hum Gene Ther; 2002 May 01; 13(7):815-27. PubMed ID: 11975848
    [Abstract] [Full Text] [Related]

  • 8. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
    Shang XY, Chen HS, Zhang HG, Pang XW, Qiao H, Peng JR, Qin LL, Fei R, Mei MH, Leng XS, Gnjatic S, Ritter G, Simpson AJ, Old LJ, Chen WF.
    Clin Cancer Res; 2004 Oct 15; 10(20):6946-55. PubMed ID: 15501973
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
    Cancer; 2009 Feb 15; 115(4):800-11. PubMed ID: 19117353
    [Abstract] [Full Text] [Related]

  • 11. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O, Lupu A, Schmidt S, Condomines M, Belle S, Maier A, Hose D, Neuber B, Moos M, Kleist C, Terness P, Ho AD, Goldschmidt H, Klein B, Hundemer M.
    J Immunother; 2009 Feb 15; 32(6):613-21. PubMed ID: 19483648
    [Abstract] [Full Text] [Related]

  • 12. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
    Rodolfo M, Luksch R, Stockert E, Chen YT, Collini P, Ranzani T, Lombardo C, Dalerba P, Rivoltini L, Arienti F, Fossati-Bellani F, Old LJ, Parmiani G, Castelli C.
    Cancer Res; 2003 Oct 15; 63(20):6948-55. PubMed ID: 14583496
    [Abstract] [Full Text] [Related]

  • 13. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma.
    Ryschich E, Nötzel T, Hinz U, Autschbach F, Ferguson J, Simon I, Weitz J, Fröhlich B, Klar E, Büchler MW, Schmidt J.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):498-504. PubMed ID: 15701833
    [Abstract] [Full Text] [Related]

  • 14. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
    Yang B, He Y, Sun DL, Zou Y, Qin XH, Huang BH.
    Zhonghua Yi Xue Za Zhi; 2008 Jul 22; 88(28):1956-60. PubMed ID: 19062734
    [Abstract] [Full Text] [Related]

  • 15. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y.
    Clin Cancer Res; 2008 Oct 15; 14(20):6487-95. PubMed ID: 18927288
    [Abstract] [Full Text] [Related]

  • 16. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals.
    Forsberg O, Carlsson B, Malmström PU, Ullenhag G, Tötterman TH, Essand M.
    Prostate; 2009 Jan 01; 69(1):70-81. PubMed ID: 18814178
    [Abstract] [Full Text] [Related]

  • 17. Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial.
    Kubuschok B, Pfreundschuh M, Breit R, Hartmann F, Sester M, Gärtner B, König J, Murawski N, Held G, Zwick C, Neumann F.
    Hum Gene Ther; 2012 Dec 01; 23(12):1224-36. PubMed ID: 22966960
    [Abstract] [Full Text] [Related]

  • 18. Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer.
    Elkord E, Williams PE, Kynaston H, Rowbottom AW.
    Int Immunol; 2005 Oct 01; 17(10):1315-25. PubMed ID: 16141246
    [Abstract] [Full Text] [Related]

  • 19. Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2.
    Yoshimura C, Nomura S, Kanazawa S, Kuwana M, Muramatsu M, Yamaguchi K, Fukuhara S.
    J Cancer Res Clin Oncol; 2002 Nov 01; 128(11):581-8. PubMed ID: 12458337
    [Abstract] [Full Text] [Related]

  • 20. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
    Bae J, Martinson JA, Klingemann HG.
    Clin Cancer Res; 2005 Feb 15; 11(4):1629-38. PubMed ID: 15746068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.